A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Harari D, Orr I, Rotkopf R, Baranzini SE, Schreiber G
Hum Mol Genet. 2015 Feb 26. PMID: 25721402.Abstract